Compare Cassava Sciences Inc (FLNA) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Roundhill Magnificent Seven ETF — how do they compare? Cassava Sciences Inc trades at $1.09 (market cap $53.14M), while Roundhill Magnificent Seven ETF trades at $68.92. The key difference: Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | MAGS | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Sector/Thematic |
52-Week High | $4.64 | $70.94 |
52-Week Low | $1.09 | $55.39 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
MAGS (Roundhill Magnificent Seven ETF) trades at $68.76, up 1.96% with a bullish technical signal from moving averages but overbought RSI readings. The ETF holds seven mega-cap tech stocks equally weighted, benefiting from AI-driven momentum but facing high concentration risk. Recent news highlights AI spending shifts from chipmakers to hyperscalers, with MAGS mentioned as a key vehicle for Magnificent Seven exposure.
Outlook remains positive due to AI infrastructure growth, but valuations are compressed for hyperscalers like Amazon and Microsoft. Risks include reliance on tech sector performance and potential rotation to small-caps. Analyst sentiment is mixed, with some seeing upside as AI revenues outpace capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
